| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USD459798 | SANOFI AVENTIS US | Pill tablet |
Sep, 2015
(8 years ago) | |
| US5635485 | SANOFI AVENTIS US | Erythromycin compounds |
Apr, 2018
(6 years ago) | |
Ketek is owned by Sanofi Aventis Us.
Ketek contains Telithromycin.
Ketek has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Ketek are:
- USD459798
- US5635485
Ketek was authorised for market use on 09 February, 2005.
Ketek is available in tablet;oral dosage forms.
Ketek can be used as treatment of community acquired pneumonia, acute exacerbation of chronic bronchitis, and acute bacterial sinusitis caused by susceptible strains of designated microorganisms in patients 18 years and older..
The generics of Ketek are possible to be released after 01 April, 2018.
Drugs and Companies using TELITHROMYCIN ingredient
Market Authorisation Date: 09 February, 2005
Treatment: Treatment of community acquired pneumonia, acute exacerbation of chronic bronchitis, and acute bacterial sinusitis caused by susceptible strains of designated microorganisms in patients 18 years and o...
Dosage: TABLET;ORAL
KETEK family patents
